Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.712
Neutral
RSI(14)
50.114
Neutral
STOCH(KDJ)(9,3,3)
32.830
Buy
ATR(14)
0.949
High Vlolatility
CCI(14)
-36.337
Neutral
Williams %R
76.591
Sell
TRIX(12,20)
0.011
Sell
StochRSI(14)
100.000
Buy
Search
Personalis Inc
PSNLAdd to Watchlist
12.660USD
+0.380+3.09%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.35BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+3.09%
5 Days
+7.47%
1 Month
-7.05%
6 Months
+35.40%
Year to Date
+59.05%
1 Year
+134.88%
Key Figures
12.750Open
12.870High
2.74MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.68%Turnover Ratio
12.280Prev. Close
12.300Low
24.86MTurnover
LossP/E Static
4.97P/B
0.00%Div Yield TTM
-31.92%ROA
11.50052wk High
0.92Volume Ratio
-81.28MNet Profit
102.48MShares
-1.0189EPS TTM
2.20Beta
-41.35%ROE
3.84052wk Low
4.64%Amplitude
1.82%Gross Margin
1.35BMarket Cap
-2.80Reward/Risk
5.14%Risk Rate
TradingKey Stock Score of Personalis Inc
Currency: USD Updated: 2026-07-31Key Insights
Personalis Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 90 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.70.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Personalis Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Personalis Inc Highlights
StrengthsRisks
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Growing
The company is in a growing phase, with the latest annual income totaling USD 69.65M.
Undervalued
The company’s latest PE is -12.43, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 65.32M shares, increasing 2.84% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 5.33M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.34.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
14.700
Target Price
+16.11%
Upside Space
Personalis Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
6
analysts
Buy
Current Rating
14.700
Target Price
+16.11%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Personalis Inc
PSNL
6
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
12.106
Buy
MA10
12.378
Buy
MA20
13.588
Sell
MA50
11.864
Buy
MA100
9.180
Buy
MA200
9.045
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Personalis Inc Info
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Ticker SymbolPSNL
CompanyPersonalis Inc
CEOHall (Christopher M)
Websitehttps://www.personalis.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52747.700
+369.700 (+0.71%)
28532.600
+371.700 (+1.32%)
7532.400
+57.300 (+0.77%)
14634.000
-115.000 (-0.78%)
63215.000
+363.000 (+0.58%)
6400.200
+34.800 (+0.55%)
78.860
-7.074 (-8.23%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4061.950
+20.520 (+0.51%)
FAQs
What is the current price of Personalis Inc (PSNL)?
The current price of Personalis Inc (PSNL) is 12.66.
What is the symbol of Personalis Inc?
The ticker symbol of Personalis Inc is PSNL.
What is the 52-week high of Personalis Inc?
The 52-week high of Personalis Inc is 11.50.
What is the 52-week low of Personalis Inc?
The 52-week low of Personalis Inc is 3.84.
What is the market capitalization of Personalis Inc?
The market capitalization of Personalis Inc is 1.35B.
Is Personalis Inc (PSNL) currently rated as Buy, Hold, or Sell?
According to analysts, Personalis Inc (PSNL) has an overall rating of Buy, with a price target of 14.70.
What is the Earnings Per Share (EPS TTM) of Personalis Inc (PSNL)?
The Earnings Per Share (EPS TTM) of Personalis Inc (PSNL) is -0.91.